Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR

Autoria(s): Conneally, E.; Swords, R.T.; Giles, F.J.; McMullin, Mary Frances; Le Coutre, P.; Langabeer, S.; Wieczorkowska, M.; McDowell, C.; Moulton, B.; Egan, K.; Dwyer, M.O.
Data(s)

01/12/2010
Identificador

http://pure.qub.ac.uk/portal/en/publications/nilotinib-300-mg-twice-daily-as-first-line-treatment-of-ph-positive-chronic-myeloid-leukemia-in-chronic-phase-updated-results-of-the-icorg-0802-phase-2-study-with-analysis-of-the-genexpert-system-versus-is-bcr-abl-rq-pcr(7ac8545e-96ef-4b1d-bd7c-3d202b3772b5).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Conneally , E , Swords , R T , Giles , F J , McMullin , M F , Le Coutre , P , Langabeer , S , Wieczorkowska , M , McDowell , C , Moulton , B , Egan , K & Dwyer , M O 2010 , ' Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR ' Blood , vol 116 , pp. 1404-1404 .
Tipo

article
Acesso ao item digital